Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 358, Issue 3, 1998, Pages 351-359

  Ferger, Boris ^a   Spratt, Chris ^a   Earl, Chris D ^a   Teismann, Peter ^a   Oertel, Wolfgang H ^a   Kuschinsky, Klaus ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Hydroxyl radicals; MPTP; Neuroprotection; Nicotine; Parkinson's disease; PBN

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; HYDROXYL RADICAL; NICOTINE; SALICYLIC ACID; SCAVENGER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; RODENT; SMOKING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BODY WEIGHT; CARDIOTONIC AGENTS; DOPAMINE; DOPAMINE AGENTS; DRUG INTERACTIONS; FREE RADICAL SCAVENGERS; HYDROXYL RADICAL; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; NICOTINE; NICOTINIC AGONISTS; NITROGEN OXIDES; PARKINSON DISEASE, SECONDARY;

EID: 0031712768     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005264     Document Type: Article

References (46)

1. Adams JD Jr, Odunze IN (1991) Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 10:161-169
2. Balfour DJK, Fagerström KO (1996) Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72:51-81
3. Beal MF (1995) Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357-366
4. Behmand RA, Harik SI (1992) Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. J Neurochem 58:776-779
5. Benowitz NL (1988) Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 319:1318-1330
6. Chan P, Delanney LE, Irwin I, Langston JW, Di Monte DA (1991) Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 57:348-351
7. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574-578
8. Court JA, Perry EK (1994) CNS nicotinic receptors - possible therapeutic targets in neurodegenerative diseases. CNS Drugs 2:216-233
9. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695
10. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38:1236-1239
11. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32:804-812
12. Ferger B, Kuschinsky K (1997) Biochemical studies support the assumption that dopamine plays a minor role in the EEG effects of nicotine. Psychopharmacology 129:192-196
13. Ferger B, Amsterdam C van, Seyfried C, Kuschinsky K (1998) Effects of α-phenyl-tert-butyl nitrone and selegiline on hydroxyl free radicals in the rat striatum produced by local application of glutamate. J Neurochem 70:276-280
14. Floyd RA, Watson JJ, Wong PK (1984) Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate products. J Biochem Biophys Methods 10:221-235
15. Fornai F, Vaglini F, Maggio R, Bonuccelli U, Corsini GU (1996) Excitatory amino acids and MPTP toxicity. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Lippincott-Raven, Philadelphia, pp 167-176
16. Fung YK, Fiske LA, Lau Y-S (1991) Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice. Gen Pharmacol 22:669-672
17. Fuxe K, Janson AM, Jansson A, Andersson K, Eneroth P, Agnati LF (1990) Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn Schmiedebergs Arch Pharmacol 341:171-181
18. Gerlach M, Riederer P, Przuntek H, Youdim MBH (1991) MPTP mechanisms of neurotoxicity and their implication for Parkinson's disease. Eur J Pharmacol - Mol Pharmacol Sect 208:279-286
19. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with phenomenology of the disease in man. J Neural Transm 103:987-1041
20. Grenhoff J, Aston-Jones G, Svensson TH (1986) Nicotinic effects on the firing of midbrain dopamine neurons. Acta Physiol Scand 128:351-358
21. Grenhoff J, Janson AM, Svensson TH, Fuxe K (1991) Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitransected at the meso-diencephalic junction. Brain Res 562:347-351
22. Hadjiconstantinou M, Hubble JP, Wemlinger TA, Neff NH (1994) Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. J Pharmacol Exp Ther 270:639-644
23. Hornykiewicz O (1988) Neurochemical pathology and the etiology of Parkinson's disease: basic facts and hypothetical possibilities. Mt Sinai J Med 55:11-20
24. Imperato A, Mulas A, DiChiara G (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132:337-338
25. Janson AM, Fuxe K, Agnati LF, Kitayama I, Harfstrand A, Andersson K, Goldstein M (1988) Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after hemitransection. Brain Res 455:332-345
26. Janson AM, Meana JJ, Goiny M, Herrera-Marschilz M (1991) Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study. Neurosci Lett 134:88-92
27. Janson AM, Fuxe K, Goldstein M (1992) Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin Invest Med 70:232-238
28. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177
29. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 [Suppl]:S161-S170
30. Lan J, Jiang DH (1997a) Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm 104:649-660
31. Lan J, Jiang DH (1997b) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104:469-181
32. +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 48:87-92
33. Leikola-Pello T, Heinämäki J, Laakso I, Ahtee L (1990) Chronic nicotine treatment changes differentially the effects of acute nicotine on the three main dopamine metabolites in mouse striatum. Naunyn Schmiedebergs Arch Pharmacol 342:400-406
34. Lichtensteiger W, Hefti F, Felix D, Huwyler T, Melamed E, Schlumpf M (1982) Stimulation of nigrostriatal dopamine neurons by nicotine. Neuropharmacology 21:963-968
35. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311:464-467
36. + toxicity in substantia nigra: protection by desferrioxamine. Brain Res 773:76-81
37. Morens DM, Grandinetti A, Reed D, White LR, Ross GW (1995) Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45:1041-1051
38. Nappi AJ, Vass E, Prota G, Memoli S (1995) The effects of hydroxyl radical attack on dopa, dopamine, 6-hydroxydopa, and 6-hydroxydopamine. Pigment Cell Res 8:283-293
39. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36:2503-2508
40. Przedborski S, Kostic V, Jackson-Lewis V, Naini S, Simonetti S, Fahn S, Carlson E, Epstein CJ, Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 12:1658-1667
41. Ramsay RR, Singer TP (1986) Energy dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261:7585-7587
42. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MHB (1989) Transition metals, ferritin, gluthathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-520
43. + toxicity on striatal dopaminergic terminals. J Neurochem 68:732-738
44. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW (1993) Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 35:67-82
45. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191-1206
46. + in vivo. Eur J Pharmacol 243:241-247